Sitaxsentan Treatment for Patients With Pulmonary Arterial Hypertension Discontinuing Bosentan
- 31 January 2007
- journal article
- research article
- Published by Elsevier
- Vol. 26 (1) , 63-69
- https://doi.org/10.1016/j.healun.2006.10.019
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Ambrisentan Therapy for Pulmonary Arterial HypertensionPublished by Elsevier ,2005
- Endothelin-1 Promotes Myofibroblast Induction through the ETA Receptor via a rac/Phosphoinositide 3-Kinase/Akt-dependent Pathway and Is Essential for the Enhanced Contractile Phenotype of Fibrotic FibroblastsMolecular Biology of the Cell, 2004
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Endothelins and Endothelin Receptor AntagonistsCirculation, 2000
- Changes in collagen metabolism in response to endothelin-1: Evidence for fibroblast heterogeneityThe International Journal of Biochemistry & Cell Biology, 1996
- Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1995
- Clearance of Circulating Endothelin-1 by ETB Receptors in RatsBiochemical and Biophysical Research Communications, 1994
- Expression of Endothelin-1 in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1993
- An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary HypertensionNew England Journal of Medicine, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958